These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23274926)

  • 1. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.
    Olver IN; Grimison P; Chatfield M; Stockler MR; Toner GC; Gebski V; Harrup R; Underhill C; Kichenadasse G; Singhal N; Davis ID; Boland A; McDonald A; Thomson D;
    Support Care Cancer; 2013 Jun; 21(6):1561-8. PubMed ID: 23274926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F; Ruggeri B; Ballatori E; Fatigoni S; Caserta C; Licitra L; Mirabile A; Ionta MT; Massidda B; Cavanna L; Palladino MA; Tocci A; Fava S; Colantonio I; Angelelli L; Ciuffreda L; Fasola G; Zerilli F
    Ann Oncol; 2015 Jun; 26(6):1248-1253. PubMed ID: 25743855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
    Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
    J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
    Hamada S; Hinotsu S; Kawai K; Yamada S; Narita S; Kamba T; Nishiyama H; Arai Y; Habuchi T; Ogawa O; Kawakami K
    Support Care Cancer; 2014 Aug; 22(8):2161-6. PubMed ID: 24652048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
    Adra N; Albany C; Brames MJ; Case-Eads S; Johnson CS; Liu Z; Fausel CA; Breen T; Hanna NH; Hauke RJ; Picus J; Einhorn LH
    Support Care Cancer; 2016 Jul; 24(7):2837-42. PubMed ID: 26838019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis.
    Wu CE; Liaw CC
    Support Care Cancer; 2012 Oct; 20(10):2357-61. PubMed ID: 22187110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
    Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
    Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
    Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
    Einhorn LH; Brames MJ; Dreicer R; Nichols CR; Cullen MT; Bubalo J
    Support Care Cancer; 2007 Nov; 15(11):1293-1300. PubMed ID: 17436025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
    Abdel-Malek R; Abbas N; Shohdy KS; Ismail M; Fawzy R; Salem DS; Safwat E
    J Egypt Natl Canc Inst; 2017 Sep; 29(3):155-158. PubMed ID: 28844591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK; Wu CE; Liaw CC
    Biomed J; 2016 Feb; 39(1):60-6. PubMed ID: 27105599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.